FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin

The US Food and Drug Administration (FDA) on Thursday approved Amgen’s Kanjinti (trastuzumab-anns), which is the fifth biosimilar to be approved for Roche’s Herceptin (trastuzumab) and 20th biosimilar overall.